Needham & Co upgrades Vertex Pharmaceuticals (Nasdaq: VRTX) from Hold to Buy. Price target $39.

Needham analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE